What happened with LTRN today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Lantern Pharma is a clinical-stage cancer-drug developer. Its RADR platform analyzes cancer and patient data using artificial intelligence to identify groups of patients who may respond to particular drugs and guide development. This includes revisiting compounds that other companies previously tried but failed to develop. Its main clinical candidates are LP-300, LP-184 and LP-284; LP-300 is being tested in never-smokers with a type of non-small cell lung cancer.
None of its candidates has marketing approval. Apart from a research grant, Lantern has not generated revenue and has financed operations mainly by selling shares. It retains worldwide commercialization rights to its main candidates and is considering licensing them to other pharmaceutical companies or working with partners. It could also build its own sales force closer to approval, but it currently has no sales or distribution capabilities. Future drug sales would depend partly on coverage and reimbursement from government health programs and private insurers.
The business depends on completing clinical development, demonstrating safety and effectiveness, and obtaining regulatory approval before selling medicines. Lantern needs additional funding to complete its trials and relies on outside research providers and manufacturers to conduct studies and supply its drug candidates.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Allarity Therapeutics competes with Lantern Pharma in using tumor gene expression to identify patients likely to benefit from cancer drugs, but also stands to receive payments from Lantern if LP-100 reaches milestones or generates sales. Watch LP-100 progress: Allarity retains milestone rights and royalties on future commercial net sales.
Recursion Pharmaceuticals offers a comparison for Lantern Pharma's AI-guided drug development: both use proprietary biological data and machine learning to discover and advance their own experimental medicines. Recursion's clinical results are worth watching for evidence that this approach can translate into treatments, while its platform also develops drug pipelines for partners.
Candel Therapeutics competes in the lung- and brain-cancer areas Lantern Pharma is targeting, but develops virus-based treatments rather than Lantern's small-molecule drugs. Its trial results in non-small cell lung cancer and recurrent high-grade glioma provide a comparison for the treatments Lantern is developing in those areas.
Foghorn Therapeutics adds competition for Lantern Pharma in non-small cell lung cancer, where Lantern is developing treatments for biomarker-defined patients. Watch Foghorn's FHD-909, which blocks the SMARCA2 protein and is in a Phase 1 trial led by Eli Lilly; Foghorn earns collaboration revenue from work under its Lilly agreement.
Apollomics overlaps Lantern Pharma's lung- and brain-cancer development markets with vebreltinib, a drug aimed at biomarker-defined non-small cell lung cancer and glioblastoma. Watch its clinical data rather than treating its partner's Chinese sales as Apollomics income: Avistone handles development and commercialization in China, and Apollomics says it has no direct financial interest in third-party development.
Actuate Therapeutics uses Lantern Pharma's platform to identify biomarker patterns for its experimental drugs, compensating Lantern with shares rather than recognized revenue. Watch whether Actuate uses the collaboration's results in further drug development, which could bring Lantern additional shares; neither company had recognized revenue under the agreement through December 31, 2025.
Recursion Pharmaceuticals, Inc. earningsRXRX
Recursion Pharmaceuticals’ report and clinical updates will show whether AI drug discovery is moving from platform work to testing medicines in people, a question facing Lantern Pharma’s RADR platform too.
Look for clinical progress in Recursion’s own drug candidates, not just continued platform work or partner programs. Candidates advancing in trials with interpretable results would show that its AI discovery approach is at least moving medicines into human testing, a useful comparison for Lantern Pharma’s development path; ongoing platform activity without corresponding drug progress would leave the approach’s ability to produce treatments unproven.
Lantern Pharma Inc. earningsThis company
Lantern Pharma’s report will show whether the research and development costs of advancing its trials still fit within the funding it can secure.
Read research and development spending alongside cash, marketable securities and financing, then check whether trials of LP-300, LP-184 and LP-284 are advancing. Controlled spending, continued trials and added funding would suggest Lantern Pharma can extend its runway without materially narrowing programs; rising costs without matching funding, or lower costs because trials have slowed, would make its late-2026 funding gap more pressing.
